Talk:Myopathy

Medicine: Genetics / Neurology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Medical genetics task force.
	This article is supported by the Neurology task force (assessed as Mid-importance).

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Myopathy.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

The following references may be useful when improving this article in the future:

Fu, Xiao-Na; Xiong, Hui (2017). "Genetic and Clinical Advances of Congenital Muscular Dystrophy". Chinese Medical Journal. 130 (21): 2624. doi:10.4103/0366-6999.217091. PMC 5678264. PMID 29067961.{{cite journal}}: CS1 maint: unflagged free DOI (link)

"Can be caused by STATINS!"

This does not appear to be the most encyclopedia-formatted set of edits in the world, yielding:

Can be caused by STATINS| Citation:BMJ 2010;340:c2197

...but the info, if legit, looks like it should be in the article. Can a subject matter expert review/edit/reformat? Thanks, --NapoliRoma (talk) 21:32, 12 April 2011 (UTC)[reply]

FDA warns for Simvastatin June 2011

After what doctors characterize as a 10 year delay in recognizing Simvastatin myopathological effects, the FDA today is headlined in national press warning for these possible effects of Simvastatin use. (It apparently is widely used, and in Sweden is the first choice statin in general practice). See further http://healthland.time.com/2011/06/09/fda-restricts-use-of-high-doses-of-cholesterol-lowering-drug-zocor/?xid=healthland-daily

This, I feel is a major matter:

1) Compared to the frequency, I presume, of congenital and acquired myopathy, this is a widely used drug by large population groups, and thus may be a major health concern. Thus it is in the public interest that this need for information be met.

2) While no connection is described in the FDA notice, one can from a layman's POV regard with suspicion Simvastatin's possible effect vis-a-vis cardiomyopathy. Which is of course a problem with mortality links, compared to skelett-musculopathy.

(On an episodic level, I stopped using it for 8 years ago after six months incapacitating use, due to pain when standing, etc. Have used Atorvastatin since with no side effects and better effect on cholesterol levels.) -- Idealist707 (talk) 21:25, 10 June 2011 (UTC)[reply]

No mention of Myofibrillar myopathy

which (by default) redirects here. - Rod57 (talk) 00:17, 10 November 2016 (UTC)[reply]